Skip to content
OpenCapital
Get started

Avalo Therapeutics AVTX Q2 2025 earnings

Reported August 7, 2025 · Before market open

Diluted EPS-$1.92Miss by $0.49
EPS estimate-$1.43

Next report

Aug 6, 2026 (In 3 weeks)
EPS estimate-$0.66

Financials

Q2 2025

Income statement

See full
Operating income-$19.3M-102%
Net income-$20.8M-121%
EPS (diluted)-$1.92+86.4%

Balance sheet

See full
Cash & equivalents$42.5M-54.6%
Total debt$679.0K-60.8%
Total equity$104.6M+868%
Total assets$126.6M+16.9%

Cash flow

See full
Operating cash flow-$11.4M+30.0%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$53.6M+316%
Enterprise value$11.76M+115%

Returns & leverage

See full
Debt / equity0×—
Current ratio12.4×+11.4×

Versus estimates

Revenue

Q4 2025$59.0KIn lineQ4 2024$192.0K

Diluted EPS

Q1 2026-$0.98Beat by $0.02Q4 2025-$0.37Beat by $1.17Q3 2025-$2.19Miss by $0.52
Q2 2025-$1.92Miss by $0.49
Q1 2025-$1.25Miss by $0.18Q4 2024-$7.95Miss by $8.53

Ask the moment Avalo Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Avalo Therapeutics report Q2 2025 earnings?
Avalo Therapeutics (AVTX) reported Q2 2025 earnings on August 7, 2025 before market open.
What were Avalo Therapeutics's Q2 2025 revenue and EPS?
Avalo Therapeutics reported diluted EPS of $-1.92 for Q2 2025.
Did Avalo Therapeutics beat estimates in Q2 2025?
EPS missed the consensus estimate of $-1.43 by $0.49.
How did Avalo Therapeutics's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, diluted EPS grew 86.4% from $-14.07.
Where can I find Avalo Therapeutics's Q2 2025 SEC filings?
You can read the 10-Q periodic report (0001628280-25-038575) directly on SEC EDGAR. The filing index links above go to sec.gov.